Cetuximab, an antibody directed against the epidermal growth factor receptor, is an effective clinical therapy for patients with colorectal, head and neck, and non-small cell lung cancer, particularly for those with KRAS and BRAF wild-type cancers. Treatment in all patients is limited eventually by ...
Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.
No comments yet
Be the first to share your thoughts!